Skip to main content
NYSE:CAH

Cardinal Health Competitors

$56.45
+0.11 (+0.20 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$55.77
$56.81
50-Day Range
$55.81
$62.46
52-Week Range
$44.65
$62.96
Volume1.96 million shs
Average Volume2.02 million shs
Market Capitalization$16.38 billion
P/E Ratio17.05
Dividend Yield3.44%
Beta1.03

Competitors

Cardinal Health (NYSE:CAH) Vs. MRNA, BSX, HUM, REGN, VRTX, and EW

Should you be buying CAH stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Cardinal Health, including Moderna (MRNA), Boston Scientific (BSX), Humana (HUM), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), and Edwards Lifesciences (EW).

Cardinal Health (NYSE:CAH) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Cardinal Health and Moderna's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardinal Health0.63%123.28%4.06%
Moderna-242.73%-28.11%-20.31%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cardinal Health and Moderna, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardinal Health03502.63
Moderna36802.29

Cardinal Health currently has a consensus price target of $62.2857, indicating a potential upside of 10.34%. Moderna has a consensus price target of $162.4375, indicating a potential upside of 1.25%. Given Cardinal Health's stronger consensus rating and higher possible upside, research analysts plainly believe Cardinal Health is more favorable than Moderna.

Institutional & Insider Ownership

82.6% of Cardinal Health shares are owned by institutional investors. Comparatively, 51.2% of Moderna shares are owned by institutional investors. 0.4% of Cardinal Health shares are owned by company insiders. Comparatively, 29.2% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Cardinal Health has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cardinal Health and Moderna's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardinal Health$152.92 billion0.11$-3,696,000,000.00$5.4510.36
Moderna$60.21 million1,069.87$-514,020,000.00($1.55)-103.50

Moderna has lower revenue, but higher earnings than Cardinal Health. Moderna is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Cardinal Health beats Moderna on 9 of the 14 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Cardinal Health (NYSE:CAH) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Institutional & Insider Ownership

90.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 82.6% of Cardinal Health shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 0.4% of Cardinal Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Boston Scientific and Cardinal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific36.59%11.77%5.57%
Cardinal Health0.63%123.28%4.06%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Boston Scientific and Cardinal Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific041212.82
Cardinal Health03502.63

Boston Scientific currently has a consensus target price of $46.5294, indicating a potential upside of 11.53%. Cardinal Health has a consensus target price of $62.2857, indicating a potential upside of 10.34%. Given Boston Scientific's stronger consensus rating and higher probable upside, research analysts plainly believe Boston Scientific is more favorable than Cardinal Health.

Valuation & Earnings

This table compares Boston Scientific and Cardinal Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$10.74 billion5.52$4.70 billion$1.5826.41
Cardinal Health$152.92 billion0.11$-3,696,000,000.00$5.4510.36

Boston Scientific has higher earnings, but lower revenue than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Boston Scientific has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Cardinal Health has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Summary

Boston Scientific beats Cardinal Health on 10 of the 15 factors compared between the two stocks.

Humana (NYSE:HUM) and Cardinal Health (NYSE:CAH) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Risk and Volatility

Humana has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Cardinal Health has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Valuation and Earnings

This table compares Humana and Cardinal Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humana$64.89 billion0.90$2.71 billion$17.8725.21
Cardinal Health$152.92 billion0.11$-3,696,000,000.00$5.4510.36

Humana has higher earnings, but lower revenue than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

91.9% of Humana shares are owned by institutional investors. Comparatively, 82.6% of Cardinal Health shares are owned by institutional investors. 0.4% of Humana shares are owned by insiders. Comparatively, 0.4% of Cardinal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Humana and Cardinal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Humana041102.73
Cardinal Health03502.63

Humana presently has a consensus price target of $470.6316, indicating a potential upside of 4.48%. Cardinal Health has a consensus price target of $62.2857, indicating a potential upside of 10.34%. Given Cardinal Health's higher possible upside, analysts plainly believe Cardinal Health is more favorable than Humana.

Dividends

Humana pays an annual dividend of $2.80 per share and has a dividend yield of 0.6%. Cardinal Health pays an annual dividend of $1.94 per share and has a dividend yield of 3.4%. Humana pays out 15.7% of its earnings in the form of a dividend. Cardinal Health pays out 35.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Humana has increased its dividend for 4 consecutive years and Cardinal Health has increased its dividend for 34 consecutive years. Cardinal Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Humana and Cardinal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Humana5.58%22.74%8.82%
Cardinal Health0.63%123.28%4.06%

Summary

Humana beats Cardinal Health on 10 of the 17 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Cardinal Health (NYSE:CAH) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Regeneron Pharmaceuticals and Cardinal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Cardinal Health0.63%123.28%4.06%

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Cardinal Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051402.74
Cardinal Health03502.63

Regeneron Pharmaceuticals presently has a consensus price target of $656.3810, suggesting a potential upside of 25.33%. Cardinal Health has a consensus price target of $62.2857, suggesting a potential upside of 10.34%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Cardinal Health.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Cardinal Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion7.14$2.12 billion$21.4724.39
Cardinal Health$152.92 billion0.11$-3,696,000,000.00$5.4510.36

Regeneron Pharmaceuticals has higher earnings, but lower revenue than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Cardinal Health has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.6% of Cardinal Health shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Cardinal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Cardinal Health on 11 of the 14 factors compared between the two stocks.

Cardinal Health (NYSE:CAH) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Valuation & Earnings

This table compares Cardinal Health and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardinal Health$152.92 billion0.11$-3,696,000,000.00$5.4510.36
Vertex Pharmaceuticals$4.16 billion13.45$1.18 billion$4.2950.43

Vertex Pharmaceuticals has lower revenue, but higher earnings than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cardinal Health and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardinal Health0.63%123.28%4.06%
Vertex Pharmaceuticals38.51%28.55%20.68%

Institutional and Insider Ownership

82.6% of Cardinal Health shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.4% of Cardinal Health shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Cardinal Health has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Cardinal Health and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardinal Health03502.63
Vertex Pharmaceuticals041512.85

Cardinal Health presently has a consensus price target of $62.2857, indicating a potential upside of 10.34%. Vertex Pharmaceuticals has a consensus price target of $292.00, indicating a potential upside of 34.97%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Cardinal Health.

Summary

Vertex Pharmaceuticals beats Cardinal Health on 11 of the 15 factors compared between the two stocks.

Cardinal Health (NYSE:CAH) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Cardinal Health and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardinal Health0.63%123.28%4.06%
Edwards Lifesciences18.18%29.00%18.10%

Risk & Volatility

Cardinal Health has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cardinal Health and Edwards Lifesciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardinal Health$152.92 billion0.11$-3,696,000,000.00$5.4510.36
Edwards Lifesciences$4.35 billion12.85$1.05 billion$1.8648.31

Edwards Lifesciences has lower revenue, but higher earnings than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

82.6% of Cardinal Health shares are owned by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are owned by institutional investors. 0.4% of Cardinal Health shares are owned by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cardinal Health and Edwards Lifesciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardinal Health03502.63
Edwards Lifesciences141102.63

Cardinal Health presently has a consensus price target of $62.2857, suggesting a potential upside of 10.34%. Edwards Lifesciences has a consensus price target of $99.7692, suggesting a potential upside of 11.04%. Given Edwards Lifesciences' higher possible upside, analysts plainly believe Edwards Lifesciences is more favorable than Cardinal Health.

Summary

Edwards Lifesciences beats Cardinal Health on 8 of the 13 factors compared between the two stocks.

pixel
Ad IPM
Legendary Crypto Analyst Names 3 Coins to Buy Instead of Coinbase
Matt McCall’s crypto portfolio has delivered multiple 1,000% winners in just months… Now he’s naming 3 tokens he believes folks should own instead of the Coinbase stock in a free report.

Cardinal Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Moderna logo
MRNA
Moderna
1.6$160.43+0.6%$64.42 billion$60.21 million-99.03
Boston Scientific logo
BSX
Boston Scientific
2.2$41.72+0.4%$59.28 billion$10.74 billion15.98
Humana logo
HUM
Humana
2.1$450.46+0.5%$58.12 billion$64.89 billion14.44
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$523.73+1.4%$56.11 billion$7.86 billion19.14
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$216.35+0.3%$56.01 billion$4.16 billion27.32
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$89.85+0.4%$55.85 billion$4.35 billion71.88
Illumina logo
ILMN
Illumina
1.6$379.48+0.4%$55.40 billion$3.54 billion88.05
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.20+0.5%$54.28 billion$30.20 billion57.34
BioNTech logo
BNTX
BioNTech
1.1$198.30+2.8%$47.89 billion$121.63 million-99.15Analyst Report
Analyst Revision
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$523.62+1.2%$44.65 billion$2.41 billion91.22
Align Technology logo
ALGN
Align Technology
2.1$559.52+1.7%$44.28 billion$2.41 billion25.46
Biogen logo
BIIB
Biogen
1.5$280.40+0.1%$42.22 billion$14.38 billion9.28
Baxter International logo
BAX
Baxter International
2.1$82.85+1.2%$41.66 billion$11.36 billion47.07
Centene logo
CNC
Centene
1.9$70.56+1.9%$41.12 billion$74.64 billion19.65Analyst Report
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$174.75+0.7%$38.62 billion$4.99 billion40.83
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.3$165.81+0.9%$34.57 billion$7.98 billion1,036.38Analyst Report
Alcon logo
ALC
Alcon
1.5$68.95+0.9%$33.66 billion$7.51 billion-46.90
McKesson logo
MCK
McKesson
2.1$199.36+2.2%$31.73 billion$231.05 billion15.17
DexCom logo
DXCM
DexCom
1.9$325.40+2.4%$31.47 billion$1.48 billion134.46
BeiGene logo
BGNE
BeiGene
1.3$323.67+1.3%$29.68 billion$428.21 million-16.02Analyst Report
ResMed logo
RMD
ResMed
1.5$195.00+0.2%$28.38 billion$2.96 billion41.85Analyst Upgrade
Seagen logo
SGEN
Seagen
1.7$147.98+0.3%$26.85 billion$916.71 million58.26Analyst Report
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.3$267.33+2.7%$26.12 billion$11.55 billion31.12Analyst Revision
Genmab A/S logo
GMAB
Genmab A/S
1.2$38.18+2.9%$25.04 billion$804.57 million29.60Analyst Report
Gap Up
AmerisourceBergen logo
ABC
AmerisourceBergen
1.5$118.11+1.3%$24.26 billion$189.89 billion-7.03Ex-Dividend
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$326.70+1.9%$24.12 billion$1.84 billion86.20
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.7$40.74+0.4%$23.86 billion$19.58 billion16.17Dividend Increase
Cerner logo
CERN
Cerner
2.0$76.50+0.4%$23.05 billion$5.69 billion29.88Insider Selling
CureVac logo
CVAC
CureVac
0.7$116.38+5.5%$21.75 billionN/A0.00
Teladoc Health logo
TDOC
Teladoc Health
1.7$137.36+1.7%$21.23 billion$553.31 million-96.06
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.79+1.8%$21.08 billion$1.30 billion25.63Insider Selling
Viatris logo
VTRS
Viatris
1.5$16.15+0.9%$19.52 billionN/A0.00Earnings Announcement
Dividend Announcement
Analyst Revision
The Cooper Companies logo
COO
The Cooper Companies
1.9$388.22+0.2%$19.08 billion$2.43 billion80.71
BIO.B
Bio-Rad Laboratories
0.7$631.85+0.0%$18.85 billion$2.31 billion5.41
Smith & Nephew logo
SNN
Smith & Nephew
2.1$42.63+0.8%$18.74 billion$5.14 billion20.90
Teleflex logo
TFX
Teleflex
2.0$393.24+0.1%$18.38 billion$2.60 billion50.61
NovoCure logo
NVCR
NovoCure
1.8$175.00+2.4%$18.10 billion$351.32 million921.10
Incyte logo
INCY
Incyte
1.6$82.27+0.4%$18.09 billion$2.16 billion-52.40
Avantor logo
AVTR
Avantor
2.0$30.90+2.3%$17.99 billion$6.04 billion257.50
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$589.74+1.9%$17.55 billion$2.31 billion5.05
Catalent logo
CTLT
Catalent
1.7$102.02+0.7%$17.38 billion$3.09 billion64.98Analyst Revision
Quest Diagnostics logo
DGX
Quest Diagnostics
1.9$132.01+2.6%$17.25 billion$7.73 billion16.32
STERIS logo
STE
STERIS
2.3$196.57+0.6%$16.78 billion$3.03 billion39.87Upcoming Earnings
Analyst Report
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$35.01+0.6%$16.56 billion$3.07 billion-61.42Analyst Report
Analyst Revision
Exact Sciences logo
EXAS
Exact Sciences
2.0$94.67+2.2%$16.24 billion$876.29 million-42.84Analyst Revision
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.5$322.71+2.0%$16.22 billion$2.62 billion53.79Analyst Report
Analyst Revision
PPD logo
PPD
PPD
1.7$46.08+0.1%$16.17 billion$4.03 billion307.20
Hologic logo
HOLX
Hologic
2.3$62.64+1.8%$16.05 billion$3.78 billion14.91
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.89+0.1%$15.97 billion$219.75 million-17.36
10x Genomics logo
TXG
10x Genomics
2.0$143.83+0.0%$15.64 billion$245.89 million-106.54
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.